Cancer Research

PARIS, May 27 /PRNewswire/ -- - Collaborative groups set out to confirm potential benefits of anticancer therapies to treat women with breast cancer A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin(R)) and the targeted therapy trastuzumab (Herceptin(R)), together with chemotherapy for the…

While estrogen is typically thought of as a "female" hormone, men produce it as well. Researchers say they have pinpointed estrogen as a key player in about half of all prostate cancers. The findings are published in the May 27 online edition of the Journal of the National Cancer Institute. Dr. Mark A. Rubin, professor of pathology and laboratory medicine, and vice chair for experimental pathology at Weill Cornell Medical College, conducted the study while at the Brigham and Women's Hospital and in collaboration with Dr. Todd Golub and other members of the Broad Institute of MIT and Harvard…

Actually, I have no proof – yet. But an article this month’s issue of Scientific American highlights the myriad therapeutic benefits of blogging, so maybe dashing off a quick article will help with my aching back… Jessica Wapner writes in her article that self-medication may be the reason the blogosphere has taken off. “Scientists (and writers) have long known about the therapeutic benefits of writing about personal experiences, thoughts and feelings. But besides serving as a stress-coping mechanism, expressive writing produces many physiological benefits. Research shows that it improves…

HALIFAX, Nova Scotia, May 23 /PRNewswire/ -- ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, congratulates Dr. Ramila Philip for being recognized as one of Pennsylvania's Best 50 Women in Business. Dr. Ramila Philip, Co-Founder and President of Immunotope Inc., received the honors from Pennsylvania Governor Edward G. Rendell. "Ramila is a champion in the biotech industry. Her clinical work in antigen discovery for ovarian and breast cancer is inspiring," commented Dr.  Randal Chase, President and CEO of IVT. Dr. Philip was selected as one of Pennsylvania's Best 50…

Researchers from the Peninsula Medical School in Cornwall, UK, have modified a photodynamic therapy (PDT) treatment that combines a topically applied cream with visible light to destroy cancer cells while leaving surrounding tissue unharmed. The cream is applied directly to skin cancers and pre-cancers, which then naturally produces a photosensitive drug. A special red light is then shone on the tumour a few hours later, to activate this light sensitive compound. This results in cellular damage and the destruction of the tumour. This technique results in reduced scarring and little or no…

TORONTO, May 22 /PRNewswire/ -- - With Photo With long summer days ahead and the delights of a good book to be enjoyed, readers around the world are picking up "Lifeliner: The Judy Taylor Story," the debut book from London-born author Shireen Jeejeebhoy. Author Photo: http://www.newscom.com/cgi-bin/prnh/20080331/298826 For Judy, summer meant books and barbecues, a time to invite her doctors and fellow patients to her home on the lake, a time for hot dogs and salads, cookies and laughter. Judy was not only the Canadian mother who made medical history as the first person to live decades on…

The human body is home to a diverse range of microorganisms, estimated to outnumber human cells in a healthy adult by ten fold. The importance of characterizing human microbiota for understanding health and disease is highlighted by the recent launch of the Human Microbiome Project by the National Institutes of Health. This report describes the investigation of healthy human skin for microbiota diversity and establishes the basis for determining a core microbiome. The Human Microbiome Project aims to characterize the microbial communities of several regions of the body, including skin, where…

ABBOTT PARK, Illinois, May 21 /PRNewswire/ -- - Three of Four HUMIRA Patients from CHARM Study in Remission at One Year Maintained Remission at Two Years Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moderate-to-severe Crohn's patients treated with HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical response, respectively, according to data presentations today at Digestive Disease Week(R) (DDW) in San Diego. DDW is the largest international gathering of physicians, researchers and academics in the fields…

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, May 21 /PRNewswire/ -- - First Diagnostic Test Based on Company's microRNA Technology Submitted for Regulatory Approval to the New York State Department of Health by Columbia University Medical Center - Additional West Coast Clinical Laboratory to Validate and Offer Tests Based on Rosetta Genomics' microRNA Technology - Two Additional microRNA-Related Patents Allowed Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading molecular diagnostics company, reported today its consolidated financial results for the quarter ended March 31, 2008 and…

HILDEN, Germany, May 21 /PRNewswire/ -- - Research Supports Replacement of Pap With HPV Test as Front-line Screen Long-term data from a study published in the International Journal of Cancer show that women screened only with a human papillomavirus (HPV) DNA test are half as likely to develop moderate to severe cervical disease over the next six years as those who get only conventional cytology (the Pap "smear"). The research followed nearly 3,000 women age 35 years and older, and assessed their HPV status using QIAGEN's digene(R) HPV Test - the only such test that is both CE-marked in…